San Raffaele Hospital at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
San Raffaele Hospital brings 8 presentations to ESGCT 2026 in Hamburg. Its work spans engineered T cells that target integrins on tumour cells and AAV gene therapy for inherited nerve disease. One strand covers treating people who have Wiskott-Aldrich syndrome under early access, and why engineered lymphocytes lose function.
| Organization | ESGCT 2026 Attendance |
|---|---|
San Raffaele Hospital Milan, Italy | |
Research hospital in Milan that hosts SR-Tiget and runs gene and cell therapy clinical trials. | Poster Wed Oct 28 1:30pm–3:30pm AAV9-mediated gene therapy to treat inherited CMT neuropathies with aberrant myelin Poster Wed Oct 28 1:30pm–3:30pm DUAL-SPECIFICITY PEPTIDE-GUIDED CAR T CELLS TARGET AVB6/AVB8 INTEGRINS FOR THERAPY, IMAGING, AND TUMOR MICROENVIRONMENT REMODELING IN PANCREATIC CANCER Poster Wed Oct 28 1:30pm–3:30pm Uncover and overcome senescence and dysfunction of genetically engineered lymphocytes for cancer immunotherapy Talk Thu Oct 29 11:15am–1:00pm Talk Thu Oct 29 12:15pm–1:00pm Poster Thu Oct 29 2:00pm–4:00pm Anti-aVB6/aVB8 integrins peptide-driven recombinant receptors for the engineering of anti-cancer living drugs Poster Thu Oct 29 2:00pm–4:00pm Use of etuvetidigene autotemcel in patients affected by Wiskott-Aldrich Syndrome in an early access setting Chair Fri Oct 30 2:30pm–4:30pm SESSION 13 Cancer models & gene therapy Cancer gene and cell therapy Talk Fri Oct 30 3:00pm–4:30pm SESSION 13 Cancer models & gene therapy Cancer gene and cell therapy |
Instantly find 20 buyers from San Raffaele Hospital
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction